Phase II Fail Wings Peregrine, but Bavituximab Moves Forth
By Randy Osborne
Thursday, June 27, 2013
Although hopes had not been high for the Phase II study in first-line non-small-cell lung cancer (NSCLC) to begin with, and the company after talking with the FDA still plans to go ahead with a Phase III trial, investors looked askance at Peregrine Pharmaceuticals Inc.'s latest snag with the cancer drug bavituximab.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.